View in EDS HTML Full Text PDF Full Text

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Saved in:
Bibliographic Details
Title: The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
Authors: Bissonnette, R.1 (AUTHOR) rbissonnette@innovaderm.ca, Maari, C.1 (AUTHOR), Forman, S.2 (AUTHOR), Bhatia, N.3 (AUTHOR), Lee, M.4 (AUTHOR), Fowler, J.5 (AUTHOR), Tyring, S.6 (AUTHOR), Pariser, D.7 (AUTHOR), Sofen, H.8 (AUTHOR), Dhawan, S.9 (AUTHOR), Zook, M.10 (AUTHOR), Zammit, D.J.11 (AUTHOR), Usansky, H.11 (AUTHOR), Denis, L.11 (AUTHOR), Rao, N.11 (AUTHOR), Song, T.12 (AUTHOR), Pavel, A.B.12 (AUTHOR), Guttman‐Yassky, E.12 (AUTHOR)
Source: British Journal of Dermatology. Oct2019, Vol. 181 Issue 4, p733-742. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00070963
DOI:10.1111/bjd.17932